Australian (ASX) Stock Market Forum

Re: AVX - Avexa Limited

Like Lazarus they have arisen!! :)

i think 'started to rise' may be a little more like it

i think, like Lazarus, they have a loong SP rise to go

ATC*Milestones*Royalties+Integrase1+IntegraseII+Valevia$65M+Allied+Coridon > 6 c

:)
 
Re: AVX - Avexa Limited

When asked by BTN whether Avexa would return to clinical investigation of ATC after that meeting, Coates indicated the company would only return to the program with a partner.

“We will not undertake clinical trials on our own after FDA,” he said.

“Even after we have gained a good go-decision from them, that what we have put to them shows that ATC could be clinically trialled in a different way.

“We would only do that if we can obtain a suitable and appropriate partner.”
 
Re: AVX - Avexa Limited

another $25k of Director's hard-earned on the line, on top of last weeks $15k...

next stop, partner, and "An immediate Phase III with near term approval potential"

:cool:
 
Partner imminent

so why are the Directors buying...

the last hiv drug licensed to a partner was Festinavir to BMS in Dec 2010...
Festinavir is a very similar and complimentary drug to ATC

interesting time frame for licensing Festinavir by BMS, note the dates below...
new data announced 13 Sept, that presumably forms the basis for a deal...
deal announced 20 Dec 2010
I make that about 3 months!

AVX announces FDA outcome 28 March
and partners about 3 months later...
June-July 2011

Festinavir, a risky early stage drug with saftey concerns = $300M
ATC a safe as houses, short and cheap to market drug with an additional $100M spent on it = $500M
share price = ?, dare I say 'priceless'

:cool:

New NRTI Festinavir Exhibits Good Anti-HIV Activity and Safety in Phase 1b/2a Study
13th of September 2010

Bristol-Myers Squibb, Oncolys complete license agreement for festinavir
20th of December 2010
 
Re: AVX - Avexa Limited

Progress reported in getting European approval of a path to market for ATC. Gave a boost to the SP.

So I sold what I had. I'm taking the view that there's more time and money to go under the bridge before the ATC (apricitibane - the anti HIV drug) story is told in full.

And I'm still not confident as to what that story will be ...

That being said, I'm looking to re-enter at lower levels. Yesterday's close of 0.038 seems a tad optimistic, for the time being.

P.
 
Re: AVX - Avexa Limited

Does anyone have a view about the best case scenario value for this stock in the next 6 months, assuming it is chugging along at this rate?

Assuming no takeover, and a partnering or royalty agreement is reached, what sales do you reckon will come with ATC and what value does that put on stock price?

Over or under 10 cents? Let's factor out the outrageous scenario where it turns out to be the cure for HIV/AIDS.
 
Re: AVX - Avexa Limited

Well, 6 months have gone by and the results (to stumpy's question) are in: Avexa spent the intervening period slumping to less than half of it's measly value of mid 0.030's, and now, glory be: it's back to 0.033.

Avexa's recent annual report continues the company song: that they're assiduously looking for a path to market for their AIDS treatment drug Apricitibane "ATC".

Meanwhile, there's been a bit of news on another of their prospects, an anti-bacterial.

Avexa's pretty well cashed up: some $18 Million.

The interesting thing is, the biotech sector is capable of pricing a company below its cash value if it is perceived that the management is tilting at windmills and wasting cash in the process. (Progen: PGL, being a case in point).

So Avexa's recent regain of lost ground can be attributed to what: that the belief is there that the path to market for ATC has got real legs? If the happy day emerges where the lights all turn green, Avexa would probably be worth about ... take your pick ... 4-fold current market cap? (currently about $28 Mill)

Well, we all want to believe it. Wonder how long before we all lose the faith?

Discl: holding as of today's close, but trading in & out.
 
Re: AVX - Avexa Limited

This stock is my weakness... bought it originally what seems like a lifetime ago under 10c and rode it up to nearly a $1.... have made some money on this, and lost some money on this..

I want to believe... but you seriously have to question if ANYTHING will ever come of this story... :banghead:

anyway - i continue to hold, and im a touch suprised as to the trading halt today??? it looks like AVX is investing in something?

so perhaps that $18M solid cash position is about to be eroded... leading to another round of tedious capital raisings... im hoping they got the announcement wrong and its about an investment BY someone in AVX... ie partner!

unlikely...


Well, we all want to believe it. Wonder how long before we all lose the faith?

Discl: holding as of today's close, but trading in & out.
 
Re: AVX - Avexa Limited

I cut my trading teeth on AVX, I took some really stupid risks during an extremely volatile time for AVX when I had absolutely no idea what I was doing. Fortunately luck was on my side to an extreme degree, I traded in and out several times per week, only lost money once or twice, multiplied my money by a factor of about five within less than two months (taking me to having more money than I'd ever had before then) and that really got me into trading, which got me into investing.

Obviously I have a soft spot for AVX, but I haven't held any for about four years now. They don't seem to have anything worth getting too excited about. At one point I was very sure ATC would go to market and I'd make a fortune, but if it ever happens it won't be soon.
 
Re: AVX - Avexa Limited

Don't think anyone would have seen this one coming. Biotech company with a failed HIV anti retroviral with a market cap of 27 million spends 4mil USD on a coal mine in the US and lends them a further 6mil USD at 6%. Bizzarre.

Related party transaction as well as the coal mine is part owned by Johnathan Lim avexa's largest shareholder with 17% of the company
 
Re: AVX - Avexa Limited

Ahh, Avexa: never boring.

At least they got the timing right: this latest weirdness comes just after the October competition close, so Yay, I won a win!

This morning however I dumped. A USA coalmine may prove to be the stroke of boldness and genius, and I'll always watch Avexa's future with interest, but the coal deal says to me that the biotech world just doesn't see commercial merit in Avexa's cupboard.

And it's news to me that there's a shortage of investment capital to fire up USA coal mines. If there was a greenfield opportunity closer to home, and sufficient expertise on the board to gauge the risks and benefits (take for example Allied Health - AHZ - who have several figures from Fortescue Metals), I'd say: yeah, okay...

But my assumption for now is that if an idea looks boneheaded, it isn't necessarily but probably is.

otherwise it's just the first step in turning Avexa into a miner per se.

So for now, bon voyage. Until I come back.
 
Re: AVX - Avexa Limited

Interesting timing.

Coal consumption in US is declining,

US Coal consumption.gif


coal stockpiles are increasing,


US Coal stocks.gif


coal export from USA is increasing


US coal exports.gif


and coal prices are falling as US exports compete with Aus, Indonesia & other exporter countries.

Cheers
Country Lad
 
Avexa Phase III

I have been holding Avexa (AVX) since 2006, stock has not performed well since my initial investments which have whittled away to almost nothing. I have been reading that they are preparing for ATC phase III trial, I have always believed if this was to happen then there is a good opportunity for this company. Whats everyone's thoughts on this stock?
 
On December 12th, 2016, Avexa Limited (AVX) changed its name and ASX code to Novita Healthcare Limited (NHL).
 
Novita Healthcare announced this morning that it has received classification from the U.S. Food and Drug Administration (FDA) for TALI Train, opening the door for the product to be launched in the United States.

TALI Train is the Company's lead digital therapeutic delivered as a drug free tool to assist in childhood development. Designed for children aged 3-8 years of age with attention difficulties, both clinical and non-clinical, as an early intervention with attention problems being the most commonly reported childhood difficulty.

The FDA has classified TALI Train as a Class 2 medical device, exempt. This means the treatment can now be sold in the U.S. without the need to conduct further clinical trials or submit a 510k application.

Today's announcement has given the NHL share price a nice lift. It is currently up 21.21% to 4c and is sitting right at support/reisistance. There was a huge day of volume on 31 August that followed the release of their FY18 financial results. It looks like a lot of sellers got taken out then as the share price did not see too much movement.

NHL appears to be at a bit of a crossroads at the moment. Hard to be sure what it's going to do from here but more good news regarding TALI Train will be sure to send it further north.

big.chart-NHL.gif
 
A year later and the news on TALi Detect finally came through. The market makers certainly took the opportunity to get involved:eek:

This significant development allows for patient reimbursement for the TALi Detect attention screening program under CPT code 961463 with the determination provided by The Pinnacle Health Group

NHL24oct2019.jpg
 
This could go again on Monday given today's price behaviour but I'd be inclined to take some off the table if it gaps at the open.

I don't chase so purely entertainment value for me:)

4.5X Bagger in two days; not bad if you can find them.

NHL25oct2019.jpg
 
The Novita Healthcare Ltd (ASX: NHL) share price is now up around 4.5x or 350% since last week.

Is an early learning childhood technology business reported and its TALi Detect platform could be delivered via the the U.S. Reimbursement Code system.

TALi Detect is described as a ‘digital attention deficit screening program’ that helps treat children with attention deficit disorder.

NHLreports that TALi Detect will now be deployed in the U.S. by Duke University Psychology, Neuroscience and Medical Centre across approximately 2,000 children.

upload_2019-10-30_13-41-30.png


629
 
Top